What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing.

Trial Profile

What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2013

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin; Warfarin
  • Indications Stent thrombosis
  • Focus Adverse reactions
  • Acronyms WOEST
  • Most Recent Events

    • 13 Feb 2013 The primary endpoint of any bleeding episode has been met, according to the Lancet.
    • 13 Feb 2013 Results published in the Lancet.
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top